Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Pre-Tax Margin
Income before tax as a percentage of revenue.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin narrows to -2149.4%
Pre-tax margin was -2149.4% in Q1 FY2026, down 1676.0 pp from a year earlier. On a trailing-twelve-month basis it was -358.9%, down 234.0 pp year over year. Over 3 fiscal years it narrowed by 139.9 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -312.2%
- Year-over-year change
- -142.5pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -312.2% | -142.5pp |
| FY2024 | 2024-12-31 | -169.7% | -20.6pp |
| FY2023 | 2023-12-31 | -149.2% | +23.2pp |
| FY2022 | 2022-12-31 | -172.4% | -11.6pp |
| FY2021 | 2021-12-31 | -160.8% | — |
Pre-Tax Margin vs competitors
How SGMO compares with its peers on the latest reported figures
- SGMO's LTM Mar 2026 pre-tax margin of -358.9% is the 5th highest of the 10 companies compared; the peer median is -1143.2%.
- Its year-over-year change of -234.0 pp is the 6th highest of 9, against a peer median of +16.0 pp.
- Over three fiscal years its change of -139.9 pp compares with a peer median of -311.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -40.9% | +108.5 pp | -38.4 pp | |
| LTM Mar 2026 | -138.9% | +250.1 pp | — | |
| LTM Mar 2026 | -184.6% | +70.2 pp | -311.0 pp | |
| LTM Mar 2026 | -297.4% | -38.1 pp | +120.4 pp | |
| LTM Mar 2026 | -358.9% | -234.0 pp | -139.9 pp | |
| LTM Mar 2026 | -1143.2% | +3402.1 pp | — | |
| FY2025 | -1764.5% | -1372.5 pp | -1664.0 pp | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2454.6% | -940.1 pp | +704.3 pp |
| LTM Mar 2026 | -3842.2% | — | -2933.3 pp | |
| LTM Mar 2026 | -9554.2% | -9545.2 pp | -2873.8 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding SGMO) | -1143.2% | +16.0 pp | -311.0 pp | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 110.7M | 111.3M | 176.23M | 57.8M | 39.55M |
| Cost of Revenue | 0 | 12.11M | 0 | 0 | 7.6M |
| Gross Profit | 110.7M | 99.19M | 176.23M | 57.8M | 31.95M |
| Gross Margin | 100.0% | 89.1% | 100.0% | 100.0% | 80.8% |
| Research & Development | 230.82M | 249.9M | 234.06M | 111.52M | 112.67M |
| Selling, General & Admin | 63.22M | 62.68M | 61.17M | 44.73M | 34.89M |
| Operating Expenses | 294.04M | 300.47M | 450.24M | 161.77M | 139.95M |
| Depreciation & Amortization | 17.64M | 12.11M | 22.19M | 9.36M | 7.6M |
| EBITDA | (160.35M) | (179.74M) | (96.8M) | (89.09M) | (115.9M) |
| EBITDA Margin | -144.9% | -161.5% | -54.9% | -154.1% | -293.0% |
| Operating Income | (183.34M) | (201.28M) | (274.01M) | (103.97M) | (108M) |
| Operating Margin | -165.6% | -180.8% | -155.5% | -179.9% | -273.1% |
| Interest Income | 5.35M | 9.43M | 11.1M | 5.86M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.35M | 9.43M | 11.1M | 5.86M | (15.5M) |
| Income Before Tax | (177.99M) | (191.85M) | (262.9M) | (98.11M) | (123.5M) |
| Pre-Tax Margin | -160.8% | -172.4% | -149.2% | -169.7% | -312.2% |
| Income Tax Expense | 306K | 429K | (5.07M) | (167K) | (568K) |
| Net Income | (178.29M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Net Margin | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% |
| EPS (Basic) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| EPS (Diluted) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| Weighted Avg Shares | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
| Weighted Avg Shares (Diluted) | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.